No Data
No Data
No Data
No Data
No Data
Form 144 | Vaxcyte(PCVX.US) Officer Proposes to Sell 497.2K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 18, $Vaxcyte(PCVX.US)$ Officer GUGGENHIME ANDREW intends to sell 8,000 shares of its common stock on Apr 18, with a total market value of approximately $497.2K. GUGGENHIM
moomoo NewsApr 18 16:11 ET
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc (NASDAQ:PCVX) estimates it will grow to ~$12 billion in the next few years. The market is currently
BenzingaApr 10 14:42 ET
Express News | Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target
Moomoo 24/7Apr 10 07:19 ET
Vaxcyte Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 47.26% Needham → $95 Reiterates Buy → Buy 03/12/2024 75.17% Mizuho $69 → $113 Maintains Buy 02/
BenzingaApr 10 07:17 ET
It's worth buying! Needham: In the wave of mergers and acquisitions in the pharmaceutical industry, these three US stocks are most likely to be acquired
Phathom Pharma, Rhythm, and Vaxcyte are most likely to be targeted by pharmaceutical companies.
Zhitong FinanceApr 8 02:23 ET
Phathom Pharma, Rhythm, Vaxcyte Most Likely Takeover Targets in Pharma - Analyst
Seeking AlphaApr 7 08:00 ET
No Data
No Data